Patents Assigned to AbbVie Inc.
  • Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
    Patent number: 9045420
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 2, 2015
    Assignee: ABBVIE INC.
    Inventors: George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura A. Hexamer, Robert A. Mantei, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Todd M. Hansen
  • Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers
    Patent number: 9045800
    Abstract: The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xL and in cancer or tumor cells, or elevated Bcl-xL polypeptide expression.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: June 2, 2015
    Assignee: AbbVie Inc.
    Inventors: Dimitri Semizarov, Tamar Uziel, David Ching Siang Huang, Mark F. van Delft, Christin Tse, Richard R. Lesniewski
  • Pharmaceutical compositions for the treatment of pain
    Patent number: 9040568
    Abstract: This invention discloses a method of treatment of osteoarthritis pain by administration of a composition containing a nicotinic acetylcholine receptor ligand and a nicotinic acetylcholine receptor subtype ?4?2 allosteric modulator. The present application also relates to compositions comprising such compounds for use in treating pain and related disorders mediated by controlling neurotransmitter release in a subject.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: May 26, 2015
    Assignee: AbbVie Inc.
    Inventors: Murali Gopalakrishnan, Chih-Hung Lee, Jianguo Ji, Tao Li, Kevin B. Sippy
  • GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
    Publication number: 20150139988
    Abstract: Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Applicant: ABBVIE, INC.
    Inventors: Boris Labkovsky, Tariq Ghayur, Georgeen Gaza-Bulseco, Pratibha Mishra, Subramanya Hedge, Sudha Krishnan
  • Dual variable domain immunoglobulins and uses thereof
    Patent number: 9035027
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: May 19, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish J. Allen
  • 7-substituted indole Mcl-1 inhibitors
    Patent number: 9035047
    Abstract: Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: May 19, 2015
    Assignee: AbbVie Inc.
    Inventors: Xilu Wang, Xiaohong Song, Steven W. Elmore, Milan Bruncko, David J. Madar, Andrew J. Souers, Lisa A. Hasvold, Le Wang, Zhi-Fu Tao, Aaron R. Kunzer
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9034875
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 19, 2015
    Assignee: ABBVIE INC.
    Inventors: George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Andrew J. Souers, Zhi-Fu Tao, Gary T. Wang, Le Wang, Robert Mantei, Todd M. Hansen
  • Tamper-evident package
    Patent number: 9033153
    Abstract: Tamper-evident package comprises a container, a primary cap, and a secondary cap. The container comprises a sidewall defining a chamber and a rim defining a mouth to the chamber. The primary cap is removably-attachable to the rim of the container to selectively close the mouth of the container. The secondary cap is positioned over the primary cap to prevent removal of the primary cap when positioned thereover. The secondary cap includes a single-use lock, such as a cable tie, to secure the secondary cap in position over the primary cap. The package thus provides evidence that someone has tampered with or attempted to tamper with the container if the single-use lock is removed or damaged. Method of using the tamper-evident package is also disclosed.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: May 19, 2015
    Assignee: Abbvie Inc.
    Inventors: Ralph H. Lambalot, Arlene F. Limanek
  • Solid compositions
    Patent number: 9034832
    Abstract: The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: May 19, 2015
    Assignee: AbbVie Inc.
    Inventors: Yi Gao, Geoff Zhang
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9029404
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: George A. Doherty, Steven W. Elmore, Laura A. Hexamer, Robert A. Mantei, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Todd M. Hansen
  • Dual variable domain immunoglobulins and uses thereof
    Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Agents for treating pain and uses thereof
    Patent number: 9029361
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Pramila A. Bhatia, John T. Randolph, Michael R. Schrimpf, Qingwei I. Zhang
  • Isoxazolines as therapeutic agents
    Patent number: 9029409
    Abstract: The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: David J. Calderwood, Eric C. Breinlinger, Steven L. Swann, Venkata Srikanth Chitty, Subramanya Seetharama Shastry Hosahalli, Subhendu Mukherjee, Siva Sanjeeva Rao Thunuguntla
  • COMPOSITIONS CONTAINING KINASE INHIBITORS
    Publication number: 20150126545
    Abstract: A composition comprises a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea, in a mixture comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. The composition is suitable for dilution with an IV solution for administration to a subject in need thereof for treatment of a cancer.
    Type: Application
    Filed: December 14, 2012
    Publication date: May 7, 2015
    Applicant: AbbVie Inc.
    Inventors: Yi Shi, Josh M. Lipari, Brian E. Padden, Lloyd S. Dias, Julie K. Spence
  • JAK1 SELECTIVE INHIBITOR AND USES THEREOF
    Publication number: 20150118229
    Abstract: The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Applicant: ABBVIE INC.
    Inventors: Jeffrey W. Voss, Heidi S. Camp, Robert J. Padley
  • Isolation and purification of antibodies using protein a affinity chromatography
    Patent number: 9018361
    Abstract: Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 28, 2015
    Assignee: AbbVie Inc.
    Inventors: Robert K. Hickman, Qing Huang, Cheryl L. Weed, Scott T. Ennis, Barbara Perilli-Palmer, Min Wan
  • Low acidic species compositions and methods for producing and using the same using displacement chromatography
    Patent number: 9017687
    Abstract: The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: April 28, 2015
    Assignee: AbbVie, Inc.
    Inventors: Chen Wang, Germano Coppola, Chris Chumsae
  • Carboxamide compounds and their use as calpain inhibitors
    Patent number: 9018206
    Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 28, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Helmut Mack, Andreas Kling, Katja Jantos, Achim Moeller, Wilfried Hornberger, Charles W. Hutchins
  • TRPV3 modulators
    Patent number: 9012651
    Abstract: Disclosed herein are modulators of TRPV3 of formula (I) wherein X1, X2, R1, R2, Rx, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 21, 2015
    Assignee: AbbVie Inc.
    Inventors: Bruce Clapham, Phil B. Cox, Michael J. Dart, Arthur Gomtsyan, Tammie K. Jinkerson, Ryan G. Keddy, Michael E. Kort, Philip R. Kym, Mark Matulenko, Robert G. Schmidt, Clara I. Villamil, Eric A. Voight, Kevin R. Woller
  • Processes for the preparation of an apoptosis-inducing agent
    Patent number: 9006438
    Abstract: Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related to the process provided herein.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 14, 2015
    Assignee: AbbVie Inc.
    Inventors: Vincent S. Chan, Alan C. Christesen, Timothy A. Grieme, Yi-Yin Ku, Mathew M. Mulhern, Yu-Ming M. Pu